618 related articles for article (PubMed ID: 25594497)
21. Importance of protein flexibility in molecular recognition: a case study on Type-I1/2 inhibitors of ALK.
Kong X; Sun H; Pan P; Zhu F; Chang S; Xu L; Li Y; Hou T
Phys Chem Chem Phys; 2018 Feb; 20(7):4851-4863. PubMed ID: 29383359
[TBL] [Abstract][Full Text] [Related]
22. Uncovering Molecular Bases Underlying Bone Morphogenetic Protein Receptor Inhibitor Selectivity.
Alsamarah A; LaCuran AE; Oelschlaeger P; Hao J; Luo Y
PLoS One; 2015; 10(7):e0132221. PubMed ID: 26133550
[TBL] [Abstract][Full Text] [Related]
23. Synthesis and biological evaluation of novel oxazolo[5,4-d]pyrimidines as potent VEGFR-2 inhibitors.
Deng YH; Xu D; Su YX; Cheng YJ; Yang YL; Wang XY; Zhang J; You QD; Sun LP
Chem Biodivers; 2015 Apr; 12(4):528-37. PubMed ID: 25879498
[TBL] [Abstract][Full Text] [Related]
24. An evaluation of indirubin analogues as phosphorylase kinase inhibitors.
Begum J; Skamnaki VT; Moffatt C; Bischler N; Sarrou J; Skaltsounis AL; Leonidas DD; Oikonomakos NG; Hayes JM
J Mol Graph Model; 2015 Sep; 61():231-42. PubMed ID: 26364215
[TBL] [Abstract][Full Text] [Related]
25. Targeting Receptor Tyrosine Kinase VEGFR-2 in Hepatocellular Cancer: Rational Design, Synthesis and Biological Evaluation of 1,2-Disubstituted Benzimidazoles.
Abdel-Mohsen HT; Abdullaziz MA; Kerdawy AME; Ragab FAF; Flanagan KJ; Mahmoud AEE; Ali MM; Diwani HIE; Senge MO
Molecules; 2020 Feb; 25(4):. PubMed ID: 32053964
[TBL] [Abstract][Full Text] [Related]
26. Effect of hydrophobic and hydrogen bonding interactions on the potency of ß-alanine analogs of G-protein coupled glucagon receptor inhibitors.
Venugopal PP; Das BK; Soorya E; Chakraborty D
Proteins; 2020 Feb; 88(2):327-344. PubMed ID: 31443129
[TBL] [Abstract][Full Text] [Related]
27. Protein-ligand interaction-guided discovery of novel VEGFR-2 inhibitors.
Zhang Y; Zhang M; Wang Y; Fan Y; Chen X; Yang Y; Hua Y; Xie W; Lu T; Tang W; Chen Y; Liu H
J Biomol Struct Dyn; 2020 Jun; 38(9):2559-2574. PubMed ID: 31232191
[TBL] [Abstract][Full Text] [Related]
28. Selective flexibility of side-chain residues improves VEGFR-2 docking score using AutoDock Vina.
Abreu RM; Froufe HJ; Queiroz MJ; Ferreira IC
Chem Biol Drug Des; 2012 Apr; 79(4):530-4. PubMed ID: 22188672
[TBL] [Abstract][Full Text] [Related]
29. Theoretical study on the interaction of pyrrolopyrimidine derivatives as LIMK2 inhibitors: insight into structure-based inhibitor design.
Shen M; Zhou S; Li Y; Li D; Hou T
Mol Biosyst; 2013 Oct; 9(10):2435-46. PubMed ID: 23881296
[TBL] [Abstract][Full Text] [Related]
30. De novo design of VEGFR-2 tyrosine kinase inhibitors based on a linked-fragment approach.
Liu YZ; Wang XL; Wang XY; Yu RL; Liu DQ; Kang CM
J Mol Model; 2016 Sep; 22(9):222. PubMed ID: 27558799
[TBL] [Abstract][Full Text] [Related]
31. Binding mechanism of CDK5 with roscovitine derivatives based on molecular dynamics simulations and MM/PBSA methods.
Dong K; Wang X; Yang X; Zhu X
J Mol Graph Model; 2016 Jul; 68():57-67. PubMed ID: 27371933
[TBL] [Abstract][Full Text] [Related]
32. Insights into mechanism of pyrido[2,3-d]pyrimidines as DYRK1A inhibitors based on molecular dynamic simulations.
Li JJ; Tian YL; Zhai HL; Lv M; Zhang XY
Proteins; 2016 Aug; 84(8):1108-23. PubMed ID: 27119584
[TBL] [Abstract][Full Text] [Related]
33. Conformational analysis of the DFG-out kinase motif and biochemical profiling of structurally validated type II inhibitors.
Vijayan RS; He P; Modi V; Duong-Ly KC; Ma H; Peterson JR; Dunbrack RL; Levy RM
J Med Chem; 2015 Jan; 58(1):466-79. PubMed ID: 25478866
[TBL] [Abstract][Full Text] [Related]
34. In silico insights into the identification of potential novel angiogenic inhibitors against human VEGFR-2: a new SAR-based hierarchical clustering approach.
Konidala KK; Bommu UD; Pabbaraju N
J Recept Signal Transduct Res; 2018 Aug; 38(4):372-383. PubMed ID: 30396316
[TBL] [Abstract][Full Text] [Related]
35. Understanding microscopic binding of macrophage migration inhibitory factor with phenolic hydrazones by molecular docking, molecular dynamics simulations and free energy calculations.
Xu L; Li Y; Li L; Zhou S; Hou T
Mol Biosyst; 2012 Sep; 8(9):2260-73. PubMed ID: 22739754
[TBL] [Abstract][Full Text] [Related]
36. Exploring the interaction between human focal adhesion kinase and inhibitors: a molecular dynamic simulation and free energy calculations.
Zhan JY; Zhang JL; Wang Y; Li Y; Zhang HX; Zheng QC
J Biomol Struct Dyn; 2016 Nov; 34(11):2351-66. PubMed ID: 26549408
[TBL] [Abstract][Full Text] [Related]
37. Probing the interaction mechanism of small molecule inhibitors with matriptase based on molecular dynamics simulation and free energy calculations.
Sun DR; Zheng QC; Zhang HX
J Biomol Struct Dyn; 2017 Mar; 35(4):755-764. PubMed ID: 26942570
[TBL] [Abstract][Full Text] [Related]
38. Pharmacophore and Docking Guided Virtual Screening Study for Discovery of Type I Inhibitors of VEGFR-2 Kinase.
Bhojwani HR; Joshi UJ
Curr Comput Aided Drug Des; 2017; 13(3):186-207. PubMed ID: 27981900
[TBL] [Abstract][Full Text] [Related]
39. Discovery of Potent VEGFR-2 Inhibitors based on Furopyrimidine and Thienopyrimidne Scaffolds as Cancer Targeting Agents.
Aziz MA; Serya RA; Lasheen DS; Abdel-Aziz AK; Esmat A; Mansour AM; Singab AN; Abouzid KA
Sci Rep; 2016 Apr; 6():24460. PubMed ID: 27080011
[TBL] [Abstract][Full Text] [Related]
40. 2D-QSAR study, molecular docking, and molecular dynamics simulation studies of interaction mechanism between inhibitors and transforming growth factor-beta receptor I (ALK5).
Jiang MN; Zhou XP; Sun DR; Gao H; Zheng QC; Zhang HX; Liang D
J Biomol Struct Dyn; 2018 Nov; 36(14):3705-3717. PubMed ID: 29064324
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
